We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+63.6%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$171M
AUM Growth
+$6.45M
Cap. Flow
-$10.6M
Cap. Flow %
-6.21%
Top 10 Hldgs %
71.58%
Holding
38
New
13
Increased
7
Reduced
9
Closed
7

Top Buys

1
MLNT
Melinta Therapeutics, Inc. Common Stock
MLNT
+$9.64M
2
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$7.93M
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$3.23M
4
OPNT
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
+$3.22M
5
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$3.15M

Top Sells

1
AMRN
Amarin Corp
AMRN
+$15.7M
2
BSTC
BioSpecifics Technologies Corp.
BSTC
+$8.98M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$5.62M
4
CORV
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
+$4.55M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$4.24M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
1
Amarin Corp
AMRN
$292M
$24.4M 14.27%
75,000
-208,510
-74% -$15.7M
APEN
2
DELISTED
Apollo Endosurgery, Inc.
APEN
$18.5M 10.81%
2,577,996
– –
BSTC
3
DELISTED
BioSpecifics Technologies Corp.
BSTC
$16.7M 9.76%
285,259
-176,056
-38% -$8.98M
BDSI
4
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$12.1M 7.06%
4,311,103
+2,825,101
+190% +$7.93M
CTIC
5
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$11.5M 6.7%
5,302,063
+1,252,765
+31% +$3.1M
VIVE
6
DELISTED
VIVEVE MED INC
VIVE
$10.3M 6.03%
3,850
– –
MLNT
7
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$7.74M 4.52%
391,719
+381,279
+3,652% +$9.64M
VNDA icon
8
Vanda Pharmaceuticals
VNDA
$327M
$7.45M 4.36%
324,600
-275,400
-46% -$5.62M
CPIX icon
9
Cumberland Pharmaceuticals
CPIX
$102M
$6.96M 4.07%
1,218,401
+15,062
+1% +$88.7K
ALIM
10
DELISTED
Alimera Sciences
ALIM
$6.85M 4%
465,857
+445
+0.1% +$6.77K
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.49M 3.21%
2,324,782
+412,764
+22% +$1.03M
NVLN
12
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$5.12M 2.99%
1,728,887
-64,024
-4% -$227K
OXFD
13
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$3.67M 2.14%
+225,877
New +$3.23M
CORV
14
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$3.61M 2.11%
898,157
-1,031,865
-53% -$4.55M
OPNT
15
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$3.32M 1.94%
+185,887
New +$3.22M
FOMX
16
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.16M 1.85%
+551,078
New +$3.15M
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$3.05M 1.79%
+138,100
New +$1.87M
CDTX
18
DELISTED
Cidara Therapeutics
CDTX
$2.89M 1.69%
32,807
+11,530
+54% +$1.02M
HTGM
19
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$2.71M 1.58%
2,976
-6,408
-68% -$4.23M
ATEC icon
20
Alphatec Holdings
ATEC
$1.31B
$2.53M 1.48%
751,756
-151,468
-17% -$478K
SPRO icon
21
Spero Therapeutics
SPRO
$91.5M
$2.38M 1.39%
+226,444
New +$2.63M
MTEM
22
DELISTED
Molecular Templates, Inc.
MTEM
$2.04M 1.19%
+25,220
New +$1.93M
ALDX icon
23
Aldeyra Therapeutics
ALDX
$102M
$2M 1.17%
+145,000
New +$1.18M
ATXS
24
DELISTED
Astria Therapeutics
ATXS
$1.73M 1.01%
36,103
-3,897
-10% -$175K
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.6B
$1.32M 0.77%
+100,000
New +$1.16M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Stonepine Capital Management held 38 positions worth $171M, up 3.9% from $165M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Stonepine Capital Management withdrew a net $10.6M in Q3 2018, closing 7 positions and reducing 9 holdings. Its most notable exit was Rigel Pharmaceuticals, an estimated $4.24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Oxford Immunotec Global PLC Ordinary Shares worth $3.67M.

  • Stonepine Capital Management's largest Q3 2018 buy was Oxford Immunotec Global PLC Ordinary Shares: 225,877 shares worth $3.67M.
  • Stonepine Capital Management added most to Melinta Therapeutics, Inc. Common Stock in Q3 2018, an estimated $9.64M increase.
  • Stonepine Capital Management's biggest Q3 2018 reduction was Amarin Corp, cutting an estimated $15.7M.
  • Stonepine Capital Management fully exited Rigel Pharmaceuticals in Q3 2018, selling an estimated $4.24M.
  • Stonepine Capital Management's ten largest holdings make up 72% of its $171M portfolio in Q3 2018.
  • Stonepine Capital Management opened 13 new positions and closed 7 in Q3 2018.
  • Stonepine Capital Management's portfolio value rose 3.9% quarter-over-quarter to $171M.

Based on Stonepine Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.